BioCryst Pharmaceuticals BCRX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $885.72M+1.2% | $874.84M+45.9% | $599.82M+7.6% | $557.51M+10.7% | $503.49M+11.7% | ||
| $19.88M+4.2% | $19.08M+21.9% | $15.65M-6.1% | $16.67M+7.1% | $15.57M+26.9% | ||
| $865.83M+1.2% | $855.76M+46.5% | $584.17M+8.0% | $540.84M+10.8% | $487.91M+11.3% | ||
| 97.8%-0.1pp | 97.8%+0.4pp | 97.4%+0.4pp | 97%+0.1pp | 96.9%-0.4pp | ||
| $189.18M+13.9% | $166.13M-4.9% | $174.7M+2.1% | $171.18M+3.5% | $165.42M-5.3% | ||
| $360.73M+3.5% | $348.65M+4.6% | $333.37M+5.7% | $315.46M+9.0% | $289.33M+8.6% | ||
| $1.27B+137% | $533.85M+1.9% | $523.72M+4.1% | $503.31M+7.0% | $470.31M+3.8% | ||
| -$381.84M-212% | $340.99M+348% | $76.1M+40.4% | $54.2M+63.4% | $33.17M+1,404% | ||
| -43.1%-82.1pp | 39%+26.3pp | 12.7%+3.0pp | 9.7%+3.1pp | 6.6%+7.2pp | ||
| $75.16M-4.7% | $78.87M-11.6% | $89.19M-5.5% | $94.35M-3.2% | $97.5M-1.0% | ||
| -$72.34M+1.7% | -$73.6M+11.0% | -$82.71M+4.3% | -$86.39M-2.4% | -$84.35M+0.1% | ||
| -$454.18M-270% | $267.39M+4,141% | -$6.62M+79.4% | -$32.19M+37.1% | -$51.18M+41.1% | ||
| $3.81M+7.9% | $3.53M+63.3% | $2.16M-38.5% | $3.52M+53.7% | $2.29M+18.7% | ||
| -$457.98M-274% | $263.86M+3,106% | -$8.78M+75.4% | -$35.71M+33.2% | -$53.47M+39.8% | ||
| -51.7%-81.9pp | 30.2%+31.6pp | -1.5%+4.9pp | -6.4%+4.2pp | -10.6%+9.1pp | ||
| -$1.77-246% | $1.21+2,520% | -$0.05+72.2% | -$0.18+30.8% | -$0.26+39.5% | ||
| -$379.72M-211% | $342.38M+342% | $77.4M+39.5% | $55.48M+61.1% | $34.44M+2,756% | ||
| -42.9%-82.0pp | 39.1%+26.2pp | 12.9%+3.0pp | 10%+3.1pp | 6.8%+7.1pp | ||
| -$381.84M-212% | $340.99M+348% | $76.1M+40.4% | $54.2M+63.4% | $33.17M+1,404% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is BioCryst Pharmaceuticals's revenue?
- BioCryst Pharmaceuticals (BCRX) generated $885.7M in revenue over the trailing twelve months, up 75.9% year over year.
- Is BioCryst Pharmaceuticals profitable?
- BioCryst Pharmaceuticals is not currently profitable: it reported a net loss of $458.0M over the trailing twelve months, a -51.7% net margin.
- What are BioCryst Pharmaceuticals's profit margins?
- Gross margin is 97.8% and operating margin is -43.1%, with a -51.7% net margin.
- What is BioCryst Pharmaceuticals's earnings per share?
- BioCryst Pharmaceuticals's diluted EPS over the trailing twelve months is $-1.77.
- Where does BioCryst Pharmaceuticals's income statement data come from?
- Every line is extracted from BioCryst Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
